{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:16:37Z","timestamp":1770768997691,"version":"3.50.0"},"reference-count":13,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,10]]},"DOI":"10.1182\/bloodadvances.2024015740","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T17:13:47Z","timestamp":1763745227000},"page":"779-781","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Dreaming of a better future: drug development in myeloma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5270-104X","authenticated-orcid":false,"given":"Richa","family":"Parikh","sequence":"first","affiliation":[{"name":"1Department of Hematology and Medical Oncology, Emory University, Atlanta, GA"},{"name":"2Winship Cancer Institute of Emory University, Atlanta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Medical Oncology, Emory University, Atlanta, GA"},{"name":"2Winship Cancer Institute of Emory University, Atlanta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"issue":"1","key":"2026021015515802200_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13045-021-01109-y","article-title":"Emerging therapies for relapsed\/refractory multiple myeloma: CAR-T and beyond","volume":"14","author":"Su","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2026021015515802200_bib2","doi-asserted-by":"crossref","first-page":"7131802","DOI":"10.1155\/2020\/7131802","article-title":"Efficacy of panobinostat for the treatment of multiple myeloma","volume":"2020","author":"Eleutherakis-Papaiakovou","year":"2020","journal-title":"J Oncol"},{"key":"2026021015515802200_bib3","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.3389\/fimmu.2018.02431","article-title":"Update on PD-1\/PD-L1 inhibitors in multiple myeloma","volume":"9","author":"Jelinek","year":"2018","journal-title":"Front Immunol"},{"issue":"7","key":"2026021015515802200_bib4","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1200\/JCO.20.02259","article-title":"Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma","volume":"39","author":"Richardson","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026021015515802200_bib5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"2026021015515802200_bib6","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","article-title":"Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol"},{"issue":"5","key":"2026021015515802200_bib7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"2026021015515802200_bib8","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"2026021015515802200_bib9","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol Ther"},{"issue":"10","key":"2026021015515802200_bib10","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular adverse events associated with antibody-drug conjugates in human clinical trials","volume":"31","author":"Eaton","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"issue":"8","key":"2026021015515802200_bib11","first-page":"2594","article-title":"Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: part 1 results of a phase I\/II study","volume":"109","author":"Terpos","year":"2024","journal-title":"Haematologica"},{"issue":"9","key":"2026021015515802200_bib12","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"2026021015515802200_bib13","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood.2023023557","article-title":"Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma","volume":"144","author":"Firestone","year":"2024","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/3\/779\/2501689\/blooda_adv-2024-015740-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/3\/779\/2501689\/blooda_adv-2024-015740-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T20:52:04Z","timestamp":1770756724000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/3\/779\/548339\/Dreaming-of-a-better-future-drug-development-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015740","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,10]]},"published":{"date-parts":[[2026,1,30]]}}}